Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout. | Biokin Pharma’s iza-bren, a first-in-class ...

After a year of impairments, revenue downgrades and the ousting of its chief executive officer, Australian plasma and vaccine specialist CSL provided signs of recovery on Tuesday. In its fiscal 2026 ...

With a massive array of prescription drugs losing patent protection in the coming years, including many biologics, Sandoz has ...

With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap.  | ...

AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso ...

In the first major workforce reduction disclosed under new CEO Belén Garijo, Sanofi is laying off 229 employees from legacy Blueprint Medicines in Massachusetts as part of a post-acquisition ...

The pharmaceutical industry creates some of the most valuable products in human history: Medicines that can extend, save and better our lives. | The pharmaceutical industry creates some of the most ...

EyePoint’s stock was down more than 70% Monday after its experimental treatment for wet age-related macular degeneration (wAMD) missed on its key goal in the first of two phase 3 readouts slated for ...

Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to the Prader-Willi syndrome ...

With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | ...

AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price, according to the Institute for Clinical and Economic Review ( | ...

More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO, Alan Bash ...